Memorial Sloan Kettering Cancer Center: Glioma trials

The registry lists 20 Glioma studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 5 are open to participants now and 6 have results posted.

Early Phase 1 1Phase 1 5Phase 2 7No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Mirdametinib in People With Central Nervous System TumorsRecruitingNCT07539441Phase 1/2
• A Study of 177Lu-PSMA-617 in People With GliomasRecruitingNCT07223034Phase 1
• Glioma Developmental and HyperActive Ras Tumor (DHART) BoardRecruitingNCT05489783
• Pembrolizumab, Olaparib, and Temozolomide for People With GliomaRecruitingNCT05188508Phase 2
• Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid TumorsRecruitingNCT00870129Not applicable
• Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade GliomasCompletedNCT02849171Not applicableResults posted
• Image-Guided Stereotactic Biopsy of High Grade GliomasCompletedNCT00979810Not applicableResults posted
• Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant GliomaCompletedNCT00782756Phase 2Results posted
• Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant GliomasCompletedNCT00590954Phase 2Results posted
• Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant GliomaCompletedNCT00498927Phase 2Results posted
• Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/GlioblastomaCompletedNCT00200161Phase 2Results posted
• A Study of 68Ga-PSMA-11 PET Scans in People With Brain TumorsActive, not recruitingNCT06209567Early Phase 1
• Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages FluentlyCompletedNCT03496181
• Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator PhenotypeActive, not recruitingNCT02658279Not applicable
• Prognostic Awareness and Patient-Physician Communication in Malignant GliomaCompletedNCT02023346
• Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant GliomaCompletedNCT01392209Phase 1
• Bevacizumab in the Radiation Treatment of Recurrent Malignant GliomaCompletedNCT00595322Not applicable
• Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant GliomaCompletedNCT00036972Phase 1
• Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant GliomaCompletedNCT00005637Phase 1
• Temozolomide in Treating Patients With Recurrent Malignant GliomaCompletedNCT00004113Phase 2